Rifasutenizol (TNP-2198) is a potent and orally bioavailable dual-targeted antibacterial agent. Rifasutenizol has potent activity against microaerophilic and anaerobic bacterial pathogens.
Rifasutenizol exhibits potent bactericidal activity against key microaerophilic and anaerobic bacterial pathogens, including Helicobacter pylori, Clostridioides difficile, and Gardnerella vaginalis, including rifamycin-resistant and nitroimidazole-resistant strains[1].
References:
[1]. Ma Z, et al. Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens. J Med Chem. 2022;65(6):4481-4495.